Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis

Abstract

Introduction:

Veno-arterial extracorporeal membrane oxygenation may be used to support patients with refractory cardiogenic shock. Many patients can be successfully weaned, the ability of some medications to facilitate weaning from veno-arterial extracorporeal membrane oxygenation were reported. To date, there are limited studies investigating the impact of levosimendan on veno-arterial extracorporeal membrane oxygenation weaning. The objective of this systematic review and meta-analysis was to assess the effects of levosimendan on successful weaning from veno-arterial extracorporeal membrane oxygenation and survival in adult patients with cardiogenic shock.

Methods:

We performed a systematic review and meta-analysis (PubMed, the Cochrane Library, and the International Clinical Trials Registry Platform published from the year 2000 onwards) investigating whether levosimendan offers advantages compared to standard therapy or placebo, in cardiogenic shock adult patients treated with veno-arterial extracorporeal membrane oxygenation. The primary outcome was veno-arterial extracorporeal membrane oxygenation successful weaning, whereas secondary outcome was all-cause mortality at the longest follow-up available. We pooled risk ratio and 95% confidence interval using fixed and random effects models according to the heterogeneity.

Results:

A total of five non-randomized clinical trials comprising 557 patients were included, 299 patients for levosimendan and 258 patients for control groups. The pooled prevalence of veno-arterial extracorporeal membrane oxygenation successful weaning was 61.4% (95% confidence interval 39.8-82.9%), and all-cause mortality was 36% (95% confidence interval 29.6-48.8%). There was a significant increase in veno-arterial extracorporeal membrane oxygenation successful weaning with levosimendan compared to the controls (risk ratio = 1.42 (95% confidence interval 1.12-1.8), p for effect = 0.004, I² = 71%). A decrease risk of all-cause mortality in the levosimendan group was also observed, risk ratio = 0.62 (95% confidence interval 0.44-0.88), p for effect = 0.007, I² = 36%.

Conclusion:

The use of levosimendan on adult patients with cardiogenic shock may facilitate the veno-arterial extracorporeal membrane oxygenation weaning and reduce all-cause mortality. Few articles of this topic are available, and prospective, randomized multi-center trials are warranted to conclude decisively on the benefits of levosimendan in this setting.

Keywords

cardiogenic shock extracorporeal membrane oxygenation levosimendan weaning mortality

Get full access to this article

View all access options for this article.

References

Napp

Kühn

Bauersachs

ECMO in cardiac arrest and cardiogenic shock. Herz 2017; 42: 27–44.

Abrams

Combes

Brodie

Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 2014; 63: 2769–2778.

Combes

Brodie

Chen

, et al. The ICM research agenda on extracorporeal life support. Intensive Care Med 2017; 43: 1306–1318.

Abrams

Garan

Abdelbary

, et al. Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med 2018; 44: 717–729.

Le Gall

Follin

Cholley

, et al. Veno-arterial-ECMO in the intensive care unit: from technical aspects to clinical practice. Anaesth Crit Care Pain Med 2018; 37: 259–268.

Rao

Alouidor

Smith

, et al. Ambulatory central VA ECMO with biventricular decompression for acute cardiogenic shock. Catheter Cardiovasc Interv 2018; 92: 1002–1004.

Marasco

Lukas

McDonald

, et al. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008; 17: S41–S47.

Ortuno

Delmas

Diehl

, et al. Weaning from veno-arterial extra-corporeal membrane oxygenation: which strategy to use. Ann Cardiothorac Surg 2019; 8: E1–E8.

Aissaoui

El-Banayosy

Combes

How to wean a patient from veno-arterial extracorporeal membrane oxygenation. Intensive Care Med 2015; 41: 902–905.

10.

Aissaoui

Luyt

Leprince

, et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med 2011; 37: 1738–1745.

11.

Durinka

Bogar

Hirose

, et al. End-organ recovery is key to success for extracorporeal membrane oxygenation as a bridge to implantable left ventricular assist device. ASAIO J 2014; 60: 189–192.

12.

Brechot

Luyt

Schmidt

, et al. Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock. Crit Care Med 2013; 41: 1616–1626.

13.

Dangers

Bréchot

Schmidt

, et al. Extracorporeal membrane oxygenation for acute decompensated heart failure. Crit Care Med 2017; 45: 1359–1366.

14.

Pappalardo

Pieri

Arnaez Corada

, et al. Timing and strategy for weaning from venoarterial ECMO are complex issues. J Cardiothorac Vasc Anesth 2015; 29: 906–911.

15.

Extracorporeal Life Support Organization (ELSO). Guide-lines for adult cardiac failure (Version 1.3.2013). Ann Arbor, MI: ELSO.

16.

Affronti

di Bella

Carino

, et al. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J 2013; 59: 554–557.

17.

Distelmaier

Roth

Schrutka

, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth 2016; 117: 52–58.

18.

Papp

Csapo

Pollesello

, et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005; 23: 71–98.

19.

Ukkonen

Saraste

Akkila

, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596–607.

20.

Parissis

Adamopoulos

Antoniades

, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309–1312.

21.

Cholley

Levy

Fellahi

, et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care 2019; 23: 385.

22.

Liberati

Altman

Tetzlaff

, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.

23.

Higgins

Altman

Gotzsche

, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

24.

Wells

Shea

O’Connell

, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

25.

Neyeloff

Fuchs

Moreira

LB.

Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes 2012; 5: 52.

26.

Higgins

Thompson

Deeks

, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

27.

Wan

Wang

Liu

, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.

28.

Song

Khan

Dinnes

, et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002; 31: 88–95.

29.

Zipfel

Reiter

Barten

, et al. Levosimendan effects benefit weaning from veno-arterial extracorporeal life support. J Heart Lung Transplant 2018; 37: S383.

30.

Jacky

Rudiger

Kruger

, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-A retrospective before-and-after study. J Cardiothorac Vasc Anesth 2018; 32: 2112–2119.

31.

Vally

Ferdynus

Persichini

, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care 2019; 9: 24.

32.

Aso

Matsui

Fushimi

, et al. In-hospital mortality and successful weaning from venoarterial extracorporeal membrane oxygenation: analysis of 5,263 patients using a national inpatient database in Japan. Crit Care 2016; 20: 80.

33.

Sangalli

Avalli

Laratta

, et al. Effects of levosimendan on endothelial function and hemodynamics during weaning from veno-arterial extracorporeal life support. J Cardiothorac Vasc Anesth 2016; 30: 1449–1453.

34.

Cecconi

De Backer

Antonelli

, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014; 40: 1795–1815.

35.

Vincent

J-L

De Backer

Circulatory shock. N Engl J Med 2013; 369: 1726–1734.

36.

Landoni

Lomivorotov

Alvaro

, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376: 2021–2031.

37.

Cholley

Caruba

Grosjean

, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA 2017; 318: 548–556.

38.

Mehta

Leimberger

van Diepen

, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017; 376: 2032–2042.

39.

Lee

Lin

Yeh

, et al. Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery: a meta-analysis with trial sequential analysis. Intensive Care Med 2017; 43: 1929–1930.